Shots:

• As per the agreement, Kogyo has the right to conduct preclinical & clinical development, manufacturing & commercialization of CRE-DR-B for allergic diseases such as canine Atopic Dermatitis in Japan
• The details regarding the upfront payment, milestones & royalties remain undisclosed. These funds will be utilized by EpitoMAP & AACL for the development of CRE-DR-B overseas, humanized CRE-DR, & therapeutic vaccines against COVID-19, FIP caused by pathogenic coronavirus in cats & FIPV
• CRE-DR-B is a chimeric antibody derived from mouse x dog IgG-B mAB called CRE-DR, which targets human and canine IgEs. CRE-DR eliminates and inactivates IgE-producing B cells, the fundamental cause of allergies

Ref: PR Newswire | Image: EpitoMAP
Related News:- ASLAN Pharmaceuticals Entered into a License Agreement with Zenyaku Kogyo for the Development and Commercialization of Eblasakimab in Japan

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com